JP2003501109A5 - - Google Patents

Info

Publication number

JP2003501109A5

JP2003501109A5 JP2001502865A JP2001502865A JP2003501109A5 JP 2003501109 A5 JP2003501109 A5 JP 2003501109A5 JP 2001502865 A JP2001502865 A JP 2001502865A JP 2001502865 A JP2001502865 A JP 2001502865A JP 2003501109 A5 JP2003501109 A5 JP 2003501109A5

Authority

JP

Japan

Prior art keywords

xaa

tyr

cys

lys

amino acid

Prior art date

2000-06-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• -1 homo-Lys Chemical compound 0.000 description 74
• 150000001413 amino acids Chemical class 0.000 description 50
• 125000001183 hydrocarbyl group Chemical group 0.000 description 26
• 229930195734 saturated hydrocarbon Natural products 0.000 description 26
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 22
• UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 22
• QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 20
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 20
• QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 20
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 20
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 20
• 229960003104 ornithine Drugs 0.000 description 20
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 19
• 230000002378 acidificating effect Effects 0.000 description 16
• 239000008194 pharmaceutical composition Substances 0.000 description 13
• 238000000034 method Methods 0.000 description 9
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 8
• 239000013543 active substance Substances 0.000 description 7
• 208000002193 Pain Diseases 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 229940043131 pyroglutamate Drugs 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229940127245 spinal anesthetics Drugs 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1